Clinical Trial

. 2024 Oct 10;391(14):1360-1362.

doi: 10.1056/NEJMc2408121. Epub 2024 Sep 14.

Pembrolizumab in HER2-Positive Gastric Cancer

Yelena Y Janjigian¹, Akihito Kawazoe², Yuxian Bai³, Jianming Xu⁴, Sara Lonardi⁵, Jean Phillipe Metges⁶, Patricio Yañez⁷, Lucjan S Wyrwicz⁸, Lin Shen⁹, Yuriy Ostapenko¹⁰, Mehmet Bilici¹¹, Hyun Cheol Chung¹², Kohei Shitara², Shukui Qin¹³, Eric Van Cutsem¹⁴, Josep Tabernero¹⁵, Suxia Luo¹⁶, Mauricio Mahave¹⁷, Yong Tang¹⁸, Maeve Lowery¹⁹, Maria M F Monteiro²⁰, Linzhi Xu²¹, Chie-Schin Shih²¹, Kanu P Sharan²¹, Pooja Bhagia²¹, Sun Young Rha¹²

Affiliations

¹ Memorial Sloan Kettering Cancer Center, New York, NY janjigiy@mskcc.org.
² National Cancer Hospital East, Kashiwa, Japan.
³ Harbin Medical University Cancer Hospital, Harbin, China.
⁴ Fifth Medical Center of the People's Liberation Army, Beijing, China.
⁵ Istituto Oncologico Veneto, Padua, Italy.
⁶ University Hospital of Brest, Brest, France.
⁷ James Lind Cancer Research Center, Temuco, Chile.
⁸ Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, Poland.
⁹ Key Laboratory of Carcinogenesis and Translational Research, Beijing, China.
¹⁰ National Cancer Institute, Kyiv, Ukraine.
¹¹ Atatürk University, Erzurum, Turkey.
¹² Yonsei Cancer Center, Seoul, South Korea.
¹³ Cancer Center of the People's Liberation Army, Nanjing, China.
¹⁴ University Hospitals Gasthuisberg, Leuven, Belgium.
¹⁵ Vall d'Hebron University Hospital Institute of Oncology, Barcelona, Spain.
¹⁶ Henan Cancer Hospital, Zhengzhou, China.
¹⁷ Fundación Arturo López Pérez, Santiago, Chile.
¹⁸ Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
¹⁹ Trinity St. James's Cancer Institute, Dublin, Ireland.
²⁰ Instituto do Câncer do Ceará, Ceará, Brazil.
²¹ Merck, Rahway, NJ.

PMID: 39282917
PMCID: PMC11620791
DOI: 10.1056/NEJMc2408121

Clinical Trial

Pembrolizumab in HER2-Positive Gastric Cancer

Yelena Y Janjigian et al. N Engl J Med. 2024.

. 2024 Oct 10;391(14):1360-1362.

doi: 10.1056/NEJMc2408121. Epub 2024 Sep 14.

Authors

Affiliations

¹ Memorial Sloan Kettering Cancer Center, New York, NY janjigiy@mskcc.org.
² National Cancer Hospital East, Kashiwa, Japan.
³ Harbin Medical University Cancer Hospital, Harbin, China.
⁴ Fifth Medical Center of the People's Liberation Army, Beijing, China.
⁵ Istituto Oncologico Veneto, Padua, Italy.
⁶ University Hospital of Brest, Brest, France.
⁷ James Lind Cancer Research Center, Temuco, Chile.
⁸ Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, Poland.
⁹ Key Laboratory of Carcinogenesis and Translational Research, Beijing, China.
¹⁰ National Cancer Institute, Kyiv, Ukraine.
¹¹ Atatürk University, Erzurum, Turkey.
¹² Yonsei Cancer Center, Seoul, South Korea.
¹³ Cancer Center of the People's Liberation Army, Nanjing, China.
¹⁴ University Hospitals Gasthuisberg, Leuven, Belgium.
¹⁵ Vall d'Hebron University Hospital Institute of Oncology, Barcelona, Spain.
¹⁶ Henan Cancer Hospital, Zhengzhou, China.
¹⁷ Fundación Arturo López Pérez, Santiago, Chile.
¹⁸ Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
¹⁹ Trinity St. James's Cancer Institute, Dublin, Ireland.
²⁰ Instituto do Câncer do Ceará, Ceará, Brazil.
²¹ Merck, Rahway, NJ.

PMID: 39282917
PMCID: PMC11620791
DOI: 10.1056/NEJMc2408121

No abstract available

PubMed Disclaimer

Figures

**Figure 1.**
Kaplan-Meier estimates of overall survival in all participants (A) and in participants with PD-L1 CPS ≥1 tumors (B) at final analysis.

See this image and copyright information in PMC

Comment on

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC. Janjigian YY, et al. Nature. 2021 Dec;600(7890):727-730. doi: 10.1038/s41586-021-04161-3. Epub 2021 Dec 15. Nature. 2021. PMID: 34912120 Free PMC article. Clinical Trial.

Cited by

ERBB3 influences the ferroptosis pathway via modulation of lipid peroxidation and GSH synthesis in gastric cancer.
Jenke R, Heinrich T, Lordick F, Aigner A. Jenke R, et al. Cell Death Discov. 2025 Aug 22;11(1):398. doi: 10.1038/s41420-025-02707-2. Cell Death Discov. 2025. PMID: 40846695 Free PMC article.
Advancements and challenges in immunotherapy for gastric cancer: current approaches and future directions.
Zhang W, Chen J, Wei Z, Song J, Zha X, Wang D, Xu M. Zhang W, et al. Front Immunol. 2025 May 21;16:1592733. doi: 10.3389/fimmu.2025.1592733. eCollection 2025. Front Immunol. 2025. PMID: 40469295 Free PMC article. Review.
Conversion Surgery After Trastuzumab-Based Chemotherapy and Immunotherapy for Stage IV HER2-Positive Gastric Cancer: A Retrospective Multicenter Cohort Study.
Liang H, Liang C, Zhang J, Sun X, Huang K, Zhang H, Li G, Chen X, Zhao L. Liang H, et al. Ann Surg Oncol. 2025 Jun 26. doi: 10.1245/s10434-025-17729-4. Online ahead of print. Ann Surg Oncol. 2025. PMID: 40571894
Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings.
Fukuda K, Osumi H, Shimozaki K, Chin K, Ogura M, Fukuoka S, Udagawa S, Yoshino K, Tamba M, Wakatsuki T, Shinozaki E, Yamaguchi K, Ooki A. Fukuda K, et al. Therap Adv Gastroenterol. 2025 Apr 24;18:17562848251333538. doi: 10.1177/17562848251333538. eCollection 2025. Therap Adv Gastroenterol. 2025. PMID: 40297207 Free PMC article.
Novel immunotherapy for gastric cancer: targeting the CD47-SIRPα axis.
Ooki A, Osumi H, Shimozaki K, Yamaguchi K. Ooki A, et al. Cancer Metastasis Rev. 2025 May 29;44(2):52. doi: 10.1007/s10555-025-10269-z. Cancer Metastasis Rev. 2025. PMID: 40437298 Review.

See all "Cited by" articles

References

1. Janjigian YY, Kawazoe A, Yanez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600(7890):727–730. DOI: 10.1038/s41586-021-04161-3. - DOI - PMC - PubMed
1. Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet (London, England) 2023;402(10418):2197–2208. (In eng). DOI: 10.1016/s0140-6736(23)02033-0. - DOI - PubMed

Publication types

Actions
Actions
Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pembrolizumab in HER2-Positive Gastric Cancer

Affiliations

Pembrolizumab in HER2-Positive Gastric Cancer

Authors

Affiliations

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Associated data

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Associated data

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous